Evidence map›Paper›PMID 42484377›Full record

ArticleJCI insight2026

A loss-of-function polymorphism in the propeptide of lysyl oxidase exacerbates atherosclerosis.

In-Hyuk Jung, Junedh M Amrute, Sofia E Luna, Ryan E Wagoner, Arturo Alisio, Paul C Lee, Kendall H Burks, Joohee Oh, Hannah C Plunkett Paletta, Chul Joo Kang and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

In-Hyuk JungCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Junedh M AmruteCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Sofia E LunaCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Ryan E WagonerCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Arturo AlisioCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Paul C LeeCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Kendall H BurksCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Joohee OhCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Hannah C Plunkett PalettaCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Chul Joo KangCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.
Nathan O StitzielCenter for Cardiovascular Research, Division of Cardiology, Department of Medicine, and.

Funding

Supplement Proposal: Accelerated Genome Aggregation and Joint Variant Calling EffortUM1HG008853 · NHGRI · WASHINGTON UNIVERSITY · PI HALL, IRA M, MILBRANDT, JEFFREY D · 2016 to 2020
$76.2M
Mechanistic Studies of the Novel Human Coronary Artery Disease Gene SVEP1R01HL159171 · NHLBI · WASHINGTON UNIVERSITY · PI STITZIEL, NATHAN OLIVER · 2022 to 2025
$2.2M
NHGRI NIH HHS UM1 HG008853NHLBI NIH HHS R01 HL159171
6 · The paper itself

Abstract

A single-nucleotide missense polymorphism (rs1800449, R158Q) in the propeptide domain of lysyl oxidase (LOX-PP) is associated with increased risk of coronary artery disease (CAD) independent of changes in plasma lipid levels. Although the enzymatic function of LOX has an essential role for the cross-linking of extracellular matrix proteins in connective tissues, whether and how LOX-PP R158Q contributes to the development of atherosclerosis has not been clearly established. Here, hypercholesterolemia was induced in mice that were WT or homozygous for the LOX-PP R158Q polymorphism by adeno-associated virus-8-mediated overexpression of Pcsk9 followed by high-fat diet feeding for 16 weeks. We found that the R158Q polymorphism promoted atherosclerosis and induced proliferation of macrophages and vascular smooth muscle cells without altering LOX enzymatic activity. Using single-cell RNA sequencing, we found the transcriptional program of atherosclerotic plaques from mice harboring R158Q was strongly enriched for proliferation- and calcification-related genes in a regionally distinct manner. Together, these results establish an enzymatically independent proatherogenic role for the LOX-PP and suggest its potential as a novel therapeutic target.

Indexed as

AtherosclerosisProtein-Lysine 6-OxidaseAnimalsCell ProliferationDiet, High-FatDisease Models, AnimalExtracellular Matrix ProteinsHumansHypercholesterolemiaMacrophagesMaleMiceMuscle, Smooth, VascularPlaque, AtheroscleroticPolymorphism, Single NucleotideProprotein Convertase 9Extracellular Matrix ProteinsLox protein, mousePcsk9 protein, mouseProprotein Convertase 9Protein-Lysine 6-OxidaseAtherosclerosisCardiologyVascular biology

Identifiers

PMID42484377
PMCPMC13461166

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.